<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle20
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:63797544;
mso-list-template-ids:-1687662552;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1320235351;
mso-list-type:hybrid;
mso-list-template-ids:326261050 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.whitehall.org/grants/__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EanMuB0Cs$" target="_blank">Whitehall Foundation Grant Programs: Basic Research in Neurobiology</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">It is the Whitehall Foundation's policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized
missions. The Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: <b>Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor,
and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior.
</b>The Whitehall Foundation does not support research focused primarily on disease(s) unless it will also provide insights into normal functioning.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research Grants</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant.
Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive,
substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Grants-in-Aid</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications
will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant’s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.<br>
<b>Letter of intent due January 15, 2020; April 15, 2020; and October 1, 2020. <span style="color:red">
Med-RA deadline to receive draft documents for January deadline: January 2, 2020.</span></b></span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.michaeljfox.org/grant/ken-griffin-alpha-synuclein-imaging-competition__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EahwBay90$">Michael J. Fox Foundation Invites Proposals for Ken Griffin Alpha-Synuclein Imaging Competition</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The <a href="https://urldefense.com/v3/__https://www.michaeljfox.org/__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EajyBNnTw$" target="_self">
Michael J. Fox Foundation</a> (MJFF) has prioritized alpha-synuclein imaging as the approach most likely imaging to have an impact on therapeutic development.</span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To that end, the foundation has issued a request for applications (RFA) for investigator-initiated studies designed to accelerate development of a selective alpha-synuclein PET tracer
for use in clinical studies. The foundation encourages multidisciplinary teams to apply and id particularly interested in collaborations between academic and industry groups that have access to diverse compound libraries.</span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Projects can include compound screening, tissue binding studies, lead identification and optimization, <i>in vivo</i> testing in appropriate models, and first-in-human testing of candidate
tracers. Funding priority will be given to teams that show the greatest promise for delivering a selective tracer for human testing at the end of the funding period.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 17, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 6, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-006.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6Eabx0oEqE$" target="_blank">Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical
Trial Optional)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites the submission of applications requesting support for projects that will be conducted to
develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve cancer risk communication between patients with an inherited susceptibility to cancer (and their families) and providers so that affected individuals
can make informed clinical risk management decisions. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (<a href="https://urldefense.com/v3/__https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaZ011cWM$">https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf</a>)
Recommendation G (<a href="https://urldefense.com/v3/__https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel*ui-id-3__;Iw!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6Ea0xYMBNo$">https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3</a> ): "Sponsor initiatives
to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing,
and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas."</span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Projects that: (1) focus on delivery of culturally competent genetic counseling, especially with respect to members of underserved populations; or (2) test approaches to communicate uncertain
genetic test results to individuals with an inherited susceptibility to cancer (and their families) and examine those individuals' behavioral, psychological, and clinical outcomes are considered high priority.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 21, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 7, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-002.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EavUuUWvQ$" target="_blank">Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants
(R01 Clinical Trial Optional)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to implement an environmental
public health action plan based on research findings. Projects supported under this program are expected to employ community-engaged research methods to not only conduct research but also to seamlessly translate research findings into public health action.
This announcement reflects NIEHS goals in bi-directional communications and in supporting research to address environmental health disparities and environmental justice concerns. The Research to Action program is part of the National Institute of Environmental
Health Sciences (NIEHS) “Partnerships for Environmental Public Health” (PEPH) network (<a href="https://urldefense.com/v3/__https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaNMandFo$">https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm</a>).</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 21, 2020 and December 4, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for January deadline: January 7, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020Rheum_2019US.pdf__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EakKJxE6Y$">Pfizer 2020 Rheumatology Competitive Grant Program</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through the program, grants of up to $150,000 will be awarded in support of both clinical and basic science research on the pathogenesis and treatment of rheumatoid arthritis (RA), psoriatic
arthritis (PsA), and/or ankylosing spondylarthrosis (AS), with a focus on projects that are most relevant to improving patient care. Investigators in the United States are encouraged to apply, including young investigators in the early stages of their career.
Specific areas of interest include: </span><o:p></o:p></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">SpA — Understanding the role of JAK-STAT signaling in the pathophysiology or disease progression of spondyloarthropathies (SpA)</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">understanding epidemiology of axSpA, including risk factors, spectrum/ progression from nr-axSpA to r-axSpA/AS</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">real-world evidence regarding efficacy and safety of tofacitinib in PsA as monotherapy vs. combination with csDMARDs</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">the efficacy and safety of tofacitinib in nr-axSpA and the long-term efficacy and safety of tofacitinib in PsA and r-axSpA</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">evidence for inhibition of structural progression (x-ray) and reduced inflammation (MRI, US) in r-axSpA and PsA</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">response in patient subtypes (e.g., oligo/polyarticular in PsA)/dominant SpA features (e.g., peripheral SpA, uveitis, enthesitis, dactylitis, IBD)</span><span style="font-size:12.0pt"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">General (RA, PsA, axSpA) — Unmet medical need/disease burden reasons for lack of/under treatment, treatment switch, patient satisfaction, and physical
and psychosocial disease impact; understanding of the efficacy and safety of tofacitinib, specifically in patients with comorbid conditions; and approaches to improving management such as treating to target by monitoring response and adjusting therapy, evidence-based
treatment algorithms, and factors predictive of response to therapy.</span><span style="font-size:12.0pt"><o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 27, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: January 13, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Emotion Regulation, Aging and Mental Disorder (R21 / R01 Clinical Trial Not Allowed)</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/pa-19-095.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6Ea_gQdG_o$" target="_blank">R21</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-19-094.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EauRLsoTM$" target="_blank">R01</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements encourage applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in
middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities
are associated with typical or atypical maturational trajectories of emotion processing. Currently it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been
found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation.
It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen
emotional resilience at particular stages of the adult life cycle.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for February 5 R01 deadline: January 23, 2020. Med-RA deadline to receive draft documents for February 16 R21 deadline: February 3, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-19-012.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaepdEQH4$" target="_blank">Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability
of funding to demonstrate and enhance the utility of selected <a href="https://urldefense.com/v3/__https://commonfund.nih.gov/__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaC39GTeA$">
Common Fund</a> data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 19, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: February 6, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-052.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaqqdHTcU$" target="_blank">NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical
Trial Optional)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism
supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 24, 2020; June 24, 2020; October 20, 2020; February 24, 2021; June 24, 2021; October 20, 2021; February 24, 2022; June 24, 2022; and October 20, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for February 2020 deadline: February 11, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-022.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6Eanz8v0ss$" target="_blank">Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids
and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 11, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: February 27, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-007.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaSXPas_o$" target="_blank">Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61 / R33
Clinical Trial Not Allowed)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This RFA invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical research projects, including
clinical trials, natural history studies, and/or comparative effectiveness research. Secondary analyses should address scientific and / or clinical hypotheses that can advance the understanding or care of neurological disorders and conditions within the NINDS
mission. In this phased funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using go/no-go data-quality metrics, prior to funding of the second phase of analyses.
Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation, and analysis, as well as controlled access to
the curated datasets.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 17, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: March 4, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-006.html__;!!PhOWcWs!j8sZK71ZjLzHKBbSvU9Twu4-XxUrvIbm-P1VqB1ml0tq-0nBQN16iYjRClDhBI90NUeJ6jRIj6EaR1YCeag$" target="_blank">Impact of Alcohol on the Onset and Progression of Alzheimer’s Disease and Its Related Dementias
(R01 – Clinical Trial Optional)</a></span><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimer's disease and its related dementias. Recent longitudinal
studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimer's disease and vascular dementia. Even moderate alcohol consumption may
be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicit
research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations
between alcohol researchers and experts in Alzheimer's disease and its related dementia research.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 24, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: March 11, 2020.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b></span><o:p></o:p></p>
</div>
</body>
</html>